Imipenem/Cilistatin and Fosfomycin for Refractory Methicillin-Resistant Staphylococcus aureus Infection: a Novel Combination Therapy.
Imipenem/Cilistatin and Fosfomycin for Refractory Methicillin-Resistant Staphylococcus aureus Infection: a Novel Combination Therapy.
Antimicrob Agents Chemother. 2020 Oct 05;:
Authors: Sakoulas G
Abstract
Given that it unlikely that randomized clinical trials will yield the answers in treating the most challenging bacteremic infections caused by methicillin-resistant Staphylococcus aureus, clinicians, microbiologists, and pharmacists will have to cooperate to discover novel ways in selecting successful individualized antimicrobial therapy for these patients. An example of such a strategy was demonstrated in the identification and utilization of imipenem/cilistatin plus fosfomycin to treat a particularly recalcitrant MRSA bacteremia and spinal abscess.
PMID: 33020155 [PubMed - as supplied by publisher]
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Sakoulas G Tags: Antimicrob Agents Chemother Source Type: research
More News: Antibiotic Therapy | Chemotherapy | Clinical Trials | Infectious Diseases | Microbiology | MRSA | Staphylococcus Aureus | Superbugs